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Abstract   
Background: CHA2DS2-VASc score is a scientifically proven risk assessment score for patients with atrial fibrillation. 
It may be a good predictor of in-hospital death in COVID-19 patients. The present study aimed to evaluate the 
association between CHA2DS2-VASc score and in-hospital mortality in the prognosis of intensive care unit (ICU) 
patients with COVID-19. 
Methods: Eighty-four COVID-19 patients who were hospitalized in the ICU were retrospectively analyzed in a tertiary 
health care center, and the CHA2DS2-VASc score was determined. All analyses were performed using SPSS 
statistical software (SPSS Inc., Chicago, IL, USA, 20.0). A p-value <0.05 was considered statistically significant. 
Results: The median age of patients was 60.0 years, and most were males (75.0%). Findings of the study showed 
that the CHA2DS2-VASc score was considerably higher among the hospitalized patients than discharged patients 
(3.08 ± 1.72 vs. 1.38 ± 1.16; p<0.001), and patients who required mechanical ventilation compared to those who did 
not require mechanical ventilation (3.03 ± 1.68 vs. 1.15 ± 0.97; P <0.001), respectively. Patients with CHA2DS2-VASc 
score of ≥3 had substantially higher age [67(45-87) vs. 58(19-75); P ˂0.001], computed tomography involvement score 
[67.5(20-90) vs. 35(15-90); P ˂0.001] and need for mechanical ventilation [29(90.6%) vs. 22(42.3%); P ˂0.001]. A 
significant difference was found in oxygen saturation on admission (P =0.001) between the two groups. In-hospital 
death was significantly higher among patients with a CHA2DS2-VASc score of ≥3 (P <0.001). The CHA2DS2-VASc 
score was positively correlated with white blood cells count (r=0.257, P =0.018) and negatively correlated with the 
number of days spent in the hospital (r=-0.184, P=0.130) due to higher in-hospital death in ICU patients with COVID-
19. 
Conclusion: CHA2DS2-VASc score may be an effective tool to estimate in-hospital death in COVID-19 patients who 
were hospitalized in the ICU. 
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Background  
Coronavirus disease 2019 (COVID-19), a highly contagious 
disease due to a new type of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), had emerged in December 2019 
in Wuhan, Hubei province, China. This unique coronavirus 
disease has created an outbreak of uncommon viral pneumonia 
due to its high transmissibility, which poses an extraordinary 
threat to public health worldwide [1]. COVID-19 had spread to 
over 200 countries, resulting in more than 240 million identified 
cases with more than 49 lakhs confirmed deaths on October 22, 
2021 [2]. Several risk factors like elderly age, males,  
 
hypertension, diabetes mellitus, previous cardiovascular 
disease, and high neutrophil-lymphocyte ratio are linked to 
death in COVID-19 patients [3-5]. Acute respiratory distress 
syndrome [6], cardiac injury [7, 8], venous thromboembolism, 
and arterial thrombosis [9] are several complications of 
COVID-19. The CHA2DS2-VASc (congestive heart failure, 
hypertension, age ≥75 years [doubled], diabetes mellitus, prior 
stroke or transient ischemic attack [doubled], vascular disease, 
age 65-74 years, and sex category [female]) is a scientifically 
proven risk assessment score used to estimate the peril of 
ischemic stroke in patients with atrial fibrillation [10], and also 
predicts mortality in several cardiovascular diseases [11]. Many 
of the risk factors of CHA2DS2-VAScscore are also predictive 
risk factors for morbidity and mortality in COVID-19 [12]. So 
far, there is a dearth of literature on the relationship between 
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CHA2DS2-VASc score and COVID-19 patients [13, 14]. 
Therefore, the current study determined the association between 
the CHA2DS2-VASc score and prognosis of intensive care unit 
(ICU) patients with COVID-19 infection in terms of in-hospital 
death. 
  
Methods    
Study population   
This was a single-center, retrospective study comprising 
consecutive 84 COVID-19 patients who were hospitalized in 
the ICU of Sri Aurobindo Medical College and P.G. Institute 
between December 2, 2020, and February 18, 2021.  The 
diagnosis of COVID-19 was performed based on the World 
Health Organization’s interim guidance.  
 
Inclusion and exclusion criteria   
Patients (age >18) with laboratory-confirmed COVID-19 by 
chest computed tomography or real-time reverse transcription-
polymerase chain reaction (RRT-PCR) (using both 
nasopharyngeal and throat swab samples) examinations were 
included. Exclusion criteria were patients with serious liver 
disease, hereditary coagulation disorders, active cancer, 
chemotherapy–radiotherapy treatment, malignancy, and 
immunodeficiency. Patients were safely discharged if they met 
the following criteria: a) absence of fever last for three days, b) 
improvement in chest computed tomography, c) clinical 
disappearance of respiratory symptoms, as well as d) negative 




Baseline demographics, clinical examination, and relevant 
investigations reports like white blood cells (WBC) count, C-
reactive protein (CRP), D-dimer, ferritin, and lactate 
dehydrogenase (LDH) were consecutively obtained from 
patients' medical records. The CHA2DS2-VASc score was 
determined based on their echocardiographic and demographic 
characteristics and includes the following clinical 
characteristics: + 1 point for each factor like congestive heart 
failure, hypertension, diabetes mellitus, vascular disease, age 
between 65 and 74 years, and female gender and + 2 points for 
each factor like age ≥75 years and previous stroke/transient 
ischemic attack [10]. The study population was segregated into 
two groups based on CHA2DS2-VASc score [group I: 
CHA2DS2-VAScscore ˂3 (n=52); group II: CHA2DS2-VASc 
score ≥3 (n=32)]. 
 
Statistical analysis   
Descriptive data are represented as mean ± SD for continuous 
variables with a normal distribution, median (interquartile range 
[IQR]) for continuous variables with a non-normal distribution, 
and frequency (%) for categorical variables. The Shapiro-Wilk 
test was used to test the normality of the distribution of 
continuous variables. The independent t-test and the Mann-
Whitney U test were used to compare continuous variables with 
normal and non-normal distributions as appropriate. Chi-square 
or Fisher exact tests were used to compare categorical variables 
as appropriate. Pearson's correlation coefficient was used to 
assess the linear correlation between two variables. A 2-tailed 
p-value <0.05 was considered statistically significant. All 
analyses were performed using SPSS statistical software, 
version 20.0 (Statistical Package for Social Sciences, Inc., 




A total of 84 COVID-19 patients who were hospitalized in the 
ICU [median age: 60.0 years (range: 54.3–68.8 years); males: 
63 (75.0%)] were included in the study. Of the 84 patients, 
diabetes was the most frequent presentation [45(53.6%) 
patients], followed by hypertension [40(47.6%) patients]. Based 
on CHA2DS2-VASc score, the number of patients in grade 0, 1, 
2, 3, 4, 5, 6, 7 was 14, 13, 25, 15, 6, 4, and 1 respectively. The 
clinical profile of study patients is outlined in Table 1. 
 
Table 1 Clinical profile of study patients (n = 84) 
Patient characteristics Total (n=84) 
Age (years) 60.0(54.3-68.8) 
Male  63(75.0%) 
CT-IS 50.0(30.0-73.8) 
WBC count on admission 9500.0(6875.0-
13375.0) 
Need for mechanical ventilation 51(60.7%) 
Duration of hospital stay (days) 8.0(5.0-10.8) 
CHA2DS2-VASc score components  
Age <65 (years) 47/84(56.0%) 
Age 65–74 (years) 25/84(29.8%) 
Age ≥75 (years) 12/84(14.2%) 
Female 21/84(25.0%) 
Past medical history  
Heart Failure  11/84(13.1%) 
Hypertension 40/84(47.6%) 
Stroke/TIA/T.E. 8/84(9.5%) 
Vascular disease/MI/PAD 11/84(13.1%) 
Diabetes 45/84(53.6%) 











Acute respiratory distress syndrome 1/19(5.3%) 
Chronic kidney disease 5/19(26.3%) 
Chronic obstructive pulmonary disease 1/19(5.3%) 
HBsAg + 2/19(10.5%) 




Post CABG 1/19(5.3%) 
Relapsed non-Hodgkin lymphoma 1/19(5.3%) 
Sickle cell disease 1/19(5.3%) 








Normal<0.6 mg/Dl 27/84(32.1%) 
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Abnormal 57/84(67.9%) 
D Dimer (μg/mL) 
 








Normal (313-618 U/L) 39/84(46.4%) 
Abnormal 45/84(53.6%) 
Status   
Discharged 39/84(46.4%) 
Hospitalized 45/84(53.6%) 
AKI-acute kidney injury; CABG-coronary artery bypass grafting; 
CHA2DS2VASc-congestive heart failure, hypertension, age ≥ 75 years, diabetes 
mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, 
sex category; CRP-C-reactive protein; CT-IS-CT involvement score; HBsAg-
hepatitis B surface antigen; LDH-lactate dehydrogenase; MI-myocardial 
infarction; PAD-peripheral artery disease; TE-systemic thromboembolism; TIA-
transient ischemic attack; WBC- white blood cells. Data are presented as median 
(interquartile range) or n (%). 
 
Comparison of clinical characteristics of study patients based on 
CHA2DS2-VASc score is outlined in Table 2. The enrolled 
patients were allocated to the group I (n=52) and group II 
(n=32). Age was considerably higher in group 2 [67(45-87)] 
than group I [58(19-75)] (P=˂0.001). Patients in group II had 
substantially higher CT INV [67.5(20-90) vs. 35(15-90); p= 
˂0.001] and higher need for mechanical ventilation [29(90.6%) 
vs. 22(42.3%); p= ˂0.001] as compared to group 1. Significant 
differences were found in oxygen saturation on admission 
(p=0.001) and status of the patients (hospitalized, discharged) 
(p=<0.001) between the two groups. Association of total 
CHA2DS2-VASc score with patients' status need of mechanical 
ventilation and oxygen saturation on admission was also 
evaluated. The CHA2DS2-VASc score was considerably higher 
in hospitalized patients than in discharged patients (3.08 ± 1.72 
vs. 1.38 ± 1.16; p=<0.001). Moreover, this score was 
substantially higher in patients who required mechanical 
ventilation than those who did not (3.03 ± 1.68 vs. 1.15 ± 0.97; 
p=<0.001). On admission, CHA2DS2-VASc score was non-
significantly higher in the measured oxygen saturation<85% 
than >85% (2.63 ± 1.81 vs. 1.82 ± 1.46; p=0.02). 
 
Table 2: Comparison of clinical characteristics of study patients based on CHA2DS2VASc score (n = 84) 
Patient characteristics Total CHA2DS2VASc score  p-value 
 < 3 (n=52) ≥ 3 (n=32)  
Age (years) 58(19-75) 67(45-87) <0.001 
CT INV 35(15-90) 67.5(20-90) <0.001 
WBC count on admission 8300(3300-23100) 11000(4400-32000) 0.013 
Need for mechanical ventilation 22(42.3%) 29(90.6%) <0.001 
Duration of stay (days) 8(1-21) 6.5(1-15) 0.216 
Oxygen saturation on admission (%)    
<85% 23(44.2%) 26(81.2%) 0.001 
>85% 29(55.8%) 6(18.8%) 
 
Inflammatory markers on admission    
CRP (mg/dL)    
Normal<0.6 mg/Dl 18(34.6%) 9(28.1%) 0.536 
Abnormal 34(65.4%) 23(71.9%) 
 
D Dimer (μg/mL)    
Normal<200 μg/mL 30(57.7%) 19(59.4%) 0.879 
Abnormal 22(42.3%) 13(40.6%) 
 
Ferritin (ng/mL)    
Normal (10-291 ng/mL) 16(30.8%) 7(21.9%) 0.375 
Abnormal 36(69.2%) 25(78.1%) 
 
LDH (U/L)    
Normal (313-618 U/L) 25(48.1%) 14(43.8%) 0.699 
Abnormal 27(51.9%) 18(56.2%) 
 
Status    
Hospitalized 19(36.5%) 26(81.2%) <0.001 
Discharged  33(63.5%) 6(18.8%)  
CHA2DS2-VASc-congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex 
category; CRP-C-reactive protein; LDH-lactate dehydrogenase; WBC-white blood cells 
 
 
As shown in Table 3, no significant association was found 
between the total CHA2DS2-VASc score with inflammatory 
markers on admission. There was a significant positive 
correlation found between CHA2DS2-VASc score and WBC 
count (r=0.257, p=0.018), whereas the number of days spent in 
hospital (r=-0.184, p=0.130) was negatively correlated with the 
CHA2DS2-VASc score, but the association was found to be 




The COVID-19 is more severe in patients with underlying 
cardiovascular diseases such as complicated myocardial injury, 
myocarditis, congestive heart failure, thromboembolism, and 
arrhythmias [15]. There is a lack of a widely accepted scoring 
system for risk prediction in COVID-19 patients. However, the 
CHA2DS2-VASc score is a scientifically proven risk 
assessment score for determining the risk of thromboembolism, 
ischemic stroke, and mortality in patients with atrial 
fibrillation[10].  
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Table 3: Comparison of inflammatory markers on admission 
with total CHA2DS2-VASc score (n = 84) 






CRP (mg/dL)    
Normal<0.6 mg/dL, n=27 2.00 ± 1.54 0.358 
Abnormal, n=57 2.43 ± 1.78  
D Dimer (μg/mL)   
Normal<200 μg/mL, n=49 1.91 ± 1.71 0.006 
Abnormal, n=35 2.82 ± 1.58  
Ferritin (ng/mL)   
Normal (10-291 ng/mL), n=23 2.08 ± 1.92 0.294 
Abnormal, n=61 2.37 ± 1.63  
LDH (U/L)   
Normal (313-618 U/L), n=39 2.23 ± 1.49 0.883 
Abnormal, n=45 2.35 ± 1.89  
CHA2DS2-VASc-congestive heart failure, hypertension, age ≥ 75 years, diabetes 
mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, 
sex category; CRP-C-reactive protein; LDH-lactate dehydrogenase; SD-standard 
deviation; WBC-white blood cells. Data are represented as mean ± SD. 
 
Additionally, this score can also predict mortality and the need 
for ICU hospitalization in COVID-19 patients [13]. However, 
there is a lack of data on the correlation between CHA2DS2-
VASc score and in-hospital morality in COVID-19 patients 
who were hospitalized in the ICU [14, 16, 17]. In the 
retrospective study of ICU patients with COVID-19, we aimed 
to investigate the association between the CHA2DS2VAScscore 
and the prognosis of ICU patients with COVID-19 in terms of 
hospital mortality. The significant findings were as follows: a) 
ICU patients with COVID-19 having CHA2DS2-VASc score 
≥3 was found at high risk of death; b) higher CHA2DS2-
VAScscore was associated with a smaller number of 
hospitalization days due to higher morality; c) higher the 
CHA2DS2-VAScscore, higher the WBC count.  
 
 
Figure 1: Correlation between CHA2DS2VASc score and WBC count. 
CHA2DS2-VASc-congestive heart failure, hypertension, age ≥ 75 years, diabetes 
mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, 
sex category; WBC-white blood cells. 
 
Most of the CHA2DS2-VASc score variables have also 
emerged as prognostic risk factors in COVID-19 patients 
hospitalized in the ICU [12]. The present study demonstrated 
that COVID-19 patients had worse clinical conditions, such as 
elderly age and higher diabetes mellitus and hypertension. 
Similar to our study, Chen et al. [18] also found that 40% of the 
total population had underlying worse clinical conditions such 
as cardiovascular or cerebrovascular diseases. Likewise, many 
studies reported that 32% [6], 46.4% [19], and 40% [20] of the 
COVID-19 patients who were hospitalized in the ICU had 
underlying cardiovascular diseases, respectively. The 
development of coagulopathy adversely affects the prognosis of 
the COVID-19 patients. Following parameters should be 
assessed to detect coagulopathy: D dimer, platelet count, 
prothrombin time, and fibrinogen level; as an increased level of 
D-dimer, massive fibrin formation, CRP, ferritin levels, and 
leukocytes count on hospital admission are associated with poor 
prognosis, extended mechanical ventilation, as well as higher 
in-hospital death [21-23]. In our study, a higher incidence of 
more severe systemic inflammation, including higher levels of 
CRP, ferritin, and LDH on admission, was associated with 
higher in-hospital death in COVID-19 patients. Owing to the 
fact that the severity of COVID-19 is also based upon the 
severe systemic inflammation, data pertaining to the D-dimer, 
massive fibrin formation, CRP, ferritin levels, LDH, and 
leukocytes count on hospital admission is of paramount 
importance. The present study found higher CHA2DS2-VASc 
scores in hospitalized COVID-19 patients than in discharged 
COVID-19 patients. This may be the reason for the higher 
incidence of invasive mechanical ventilation, high levels of 
oxygen saturation, high levels of WBC counts, and shorter 
duration of hospital stay recorded in the patients with 
hospitalized patients. This finding is in accordance with 
findings reported by Quasi et al.[14]. Another study by Cetinkal 
et al.[24] also stated that the COVID-19 infection was much 
more severe in the patients with higher CHA2DS2-VASc 
scores. Based on this, the CHA2DS2-VASc score may be an 
independent predictor of in-hospital death in COVID-19 
patients who were hospitalized in the ICU.  
 
 
Figure 2. Correlation between CHA2DS2VASc score and number of days spent 
in hospital. CHA2DS2VASc-congestive heart failure, hypertension, age ≥ 75 
years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 
65 to 74 years, sex category. 
 
The design of this study entails some constraints. First, this was 
a retrospective study with a small sample size. Second, 
information regarding medications used by patients with 
hypertension, diabetes, and other diseases was not included. 
Lastly, in-hospital morality was only reported due to the 
retrospective nature of the study. Association of CHA2DS2-
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VASc scores with in-hospital death of ICU patients with 
COVID-19 warrants further investigation. 
 
Conclusion  
Assessment of CHA2DS2-VASc score can help clinicians for 
estimating in-hospital death in ICU patients with COVID-19. 
Our study showed overall high CHA2DS2-VASc scores in the 
hospitalized patients and further noted that a CHA2DS2-VASc 
score of ≥3 on hospital admission predicted in-hospital death in 
ICU patients with COVID-19. Therefore, CHA2DS2-
VAScscore can decrease the peril of deleterious events during 
hospitalization of high-risk COVID-19 patients and allow 
improvement in patients’ management. However, more studies 
are needed to confirm these findings. 
 
Abbreviation  
CHA2DS2-VASc: congestive heart failure, hypertension, age 
≥75 years [doubled], diabetes mellitus, prior stroke or transient 
ischemic attack [doubled], vascular disease, age 65-74 years, 
and sex category [female], COVID-19: Coronavirus disease 
2019, CRP: C-reactive protein, ICU: intensive care unit, IQR: 
interquartile range, LDH: lactate dehydrogenase, RRT-PCR: 
real-time reverse transcription-polymerase chain reaction, 
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, 
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